Technology Author:Yuan Zhuang Jul 27, 2023 05:16 PM (GMT+8)

Recently, Chinese medical robot developer Puncture (磅策医疗) completed an A+ round financing of nearly CNY 100 million.

1

Founded in 2019, Puncture is a company that focuses on medical robots under Harbinger Robot (哈工大机器人). The research and development team studies the common clinical characteristics of various diseases, explores the common clinical needs that need to be solved, and applies advanced robotics technology to make more specialized manufacturing subdivided field robots. The product pipeline covers serious medical and consumer medical fields. The existing hair transplant robot, surgical robot puncture navigation system, and other products cover medical aesthetics, tumor, and other fields.

According to the data, from 2004 to 2019, the global hair restoration market has shown a continuous growth trend, with a compound annual growth rate of 12.2%. As of 2019, the market size has reached USD 4.6 billion. At the same time, the global hair transplant penetration rate is generally low, while China's penetration rate of only 0.25% is already at a leading level.

Relying on in-depth clinical insight and profound technical accumulation, Puncture has independently developed the Hairo® hair transplant robot, which realizes hair recognition and intelligent planning with the help of stereo vision positioning technology, is equipped with mechanical arm force feedback protection and real-time motion compensation, and efficiently completes hair follicle extraction surgery. In June of this year, the product started clinical trials, bringing new breakthroughs to global hair transplant technology.

Up to now, the global hair transplant robot market is relatively scarce, but the most representative one is Restoration Robotics from the United States. The Artas robot developed by the company has become a leader in this field, and its technology and products sell well all over the world.

This round of financing for Puncture was led by Shenzhen Capital Group (深圳市创新投资集团), followed by Huayi Fund (华医资本). This round of funds will be used for product development, clinical certification, production capacity enhancement, and global promotion.